Trials / Conditions / Hepato Cellular Carcinoma (HCC)

Hepato Cellular Carcinoma (HCC)

20 registered clinical trials studyying Hepato Cellular Carcinoma (HCC) — 16 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC NCT07494435	Zhejiang Haichang Biotech Co., Ltd.	Phase 2
Not Yet Recruiting	Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma NCT07536789	Fudan University	Phase 2
Not Yet Recruiting	Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing L NCT07461675	University of Geneva, Switzerland	Phase 3
Not Yet Recruiting	TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellu NCT07487662	Sun Yat-sen University	Phase 2
Recruiting	Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular NCT07302919	University Hospital, Basel, Switzerland	Phase 2 / Phase 3
Not Yet Recruiting	A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma NCT07328009	Fudan University	Phase 2
Recruiting	Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy Wi NCT07276100	IRCCS Azienda Ospedaliero-Universitaria di Bologna	Phase 2
Recruiting	Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC) NCT06990659	University Hospital, Angers	N/A
Withdrawn	BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma NCT06608940	Case Comprehensive Cancer Center	Phase 1 / Phase 2
Recruiting	Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC NCT07267806	Linhui Peng	Phase 3
Not Yet Recruiting	Retrospective Clinical Validation of HepatoPredict NCT06894524	Ophiomics	—
Recruiting	Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma NCT06960863	Tanta University	—
Recruiting	PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma NCT06960954	Tanta University	—
Recruiting	HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma NCT06812039	Fudan University	Phase 2
Recruiting	PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC NCT06742424	West China Hospital	Phase 2
Recruiting	Hepatocellular Carcinoma Identification Using Delta-HLD NCT07148310	Epiliquid Holding, Inc	—
Completed	Ex-vivo Hypotermic Perfusion in Patients With Hepatocellular Carcinoma to Reduce the Incidence of Tumor Recurr NCT06720675	IRCCS Azienda Ospedaliero-Universitaria di Bologna	—
Terminated	Evaluate the Effect of Tirazamine on Primary Liver Cancer. NCT06848556	Zhejiang Raygene Pharmaceuticals Co., Ltd	Phase 1 / Phase 2
Recruiting	Effect and Mechanism of ALPPS Operation on Liver Regeneration NCT07142213	Haitao Zhao, MD	—
Completed	First Line Hepato Cellular Carcinoma (HCC) NCT00858871	Bristol-Myers Squibb	Phase 3